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Background: Antibiotic Associated Diarrhoea (AAD) and Clostridioides Difficile Infection (CDI) are of major con-
cern in spinal cord injury (SCI) rehabilitation.
Methods: Amulti-centre, randomized, double-blind, placebo-controlled (the ECLISP) trial, was conducted in three
tertiary spinal cord injury centre in the UK to assess the efficacy of consuming a probiotic beverage containing at
least 6.5 £ 109 live Lactobacillus casei Shirota (LcS) in preventing AAD and CDI and in patients with SCI and to
determine whether proton pump inhibitors (PPI) and under nutrition-risk are risk factors for AAD/CDI. LcS or pla-
cebo was given once daily for the duration of an antibiotic course and continued for 7 days thereafter. Follow up
was set at 7 and 30 days after the antibiotic course finished. The primary outcome was occurrence of AAD up to
30 days after finishing LcS/placebo. This trial is completed and registered (ISRCTN:13119162).
Findings: Between November 2014, and November 2019, 359 consenting adult SCI patients (median age:
53.3; range: 1888 years), from 3 SCI centres responsible for providing approximate 4550% of UK SCI ser-
vice, with a requirement for antibiotics due to infection were randomly allocated to receive LcS (n = 181) or
placebo (n = 178). Overall, no statistical difference was seen in occurrence of the primary outcomes of AAD at
30 days follow up (45% v 42.1%, RR: 1.071, 0.8-1.4, p = 0.639). In the secondary analyses LcS was associated
with a lower risk of AAD at 7 (19% v 35.7%, RR: 0.53, 0.290.99, p = 0.040) and 30 days follow up (28% v
52.2%, RR: 0.54, 0.320.91, p = 0.015) in the participants who took PPI regularly. Under nutrition-risk was
associated with an increased risk of AAD at 7 (RR: 1.76, 1.282.44) and 30 days follow up (RR: 1.69,
1.302.0). No intervention-related adverse events were reported during the study.
Interpretation: The present study indicates that LcS could not prevent AAD/CDI in unselected SCI patients. LcS
might have the potential to prevent AAD in the higher risk group of patients on regular PPI. Confirmatory
studies are needed to allow translation of this apparent therapeutic success into improved clinical outcomes.
Funding: Yakult Honsha Co., Ltd.
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Antibiotic associated diarrhoea (AAD), described as unexplained
diarrhoea that occurs in association with antibiotic administration, is
a common complication of antibiotic treatment. It is reported that
Research in context
Evidence before this study
The prevalence of antibiotic associated diarrhoea (AAD) and of
Clostridioides difficile infection (CDI) in patients with spinal cord
injury (PWSCI) patients are reported in range of 14.9 to 30.3%.
Probiotics, have been proposed to prevent AAD / CDI by main-
tain a healthy gut microbiota in hospitalised patients on antibi-
otic therapy.
Added value of this study
Our study identified that the use of a single strain Lactobacillus
casei Shirota (LcS) supplement could not prevent AAD in PWSCI
(44.6% v 42.1%, RR: 1.06, 0.81.4; p = 0.412) but was associated
with a lower risk of AAD at 7 (19% v 35.7%, p = 0.040) and
30 days follow up (28% v 52.2%, p = 0.015) in participants who
took PPI regularly.
Implication of all the available evidence
The present study found that LcS could not prevent AAD in
PWSCI but has the potential to prevent AAD in the higher risk
group of PWSCI on PPI and at risk of under nutrition. Confirma-
tory studies are needed to allow translation of this apparent
therapeutic success into improved clinical outcomes.
2 S. Wong et al. / EClinicalMedicine 40 (2021) 101098about 30.3% of patients will develop AAD upon administration of
antibiotics [1] but the frequency of AAD can be as high as 60% during
hospital outbreaks [2].
Infection with the recently renamed Clostridioides Difficile (CDI)
occurs most often as a consequence of disruption of the gut micro-
biota following the use of broad spectrum antibiotics, and is therefore
considered the specific cause in a subgroup of AAD. C. difficile is a
spore-forming, Gram-positive anaerobe. It is a particularly virulent
pathogen because it produces an enterotoxin and a cytotoxin, both of
which cause mucosal injury and damage to the colon. When antibi-
otic therapy disrupts this natural defence, C. difficile multiplies and
produces toxins, causing diarrhoea. In some cases, severe inflamma-
tion (C. difficile associated colitis) can develop [3].
Probiotics, defined as ‘live microorganisms which, when administered
in adequate amounts, confer a health benefit on the host’, have been pro-
posed to prevent AAD/CDI by restoring or maintaining a healthy gut
microbiome in hospitalized patients on antibiotic therapy, particularly
those on broad-spectrum antibiotics [4], but it is still unclear whether
specific probiotic strains reduce the overall incidence of AAD/CDI [5-10].
People with SCI (PWSCI) may be particularly vulnerable to diar-
rhoea and its consequences because of their long hospital stays for
acute care and rehabilitation [11]. In addition, neurogenic bladder
dysfunction as a result of SCI often leads to enhanced risk of symp-
tomatic urinary tract infections, due to defective urine storage, blad-
der stones, foreign bodies or residual urine in the bladder. The use of
invasive devices such as urinary catheters further increases the need
for antibiotics and the risks of their undesirable effects, including
AAD and CDI. Newly injured PWSCI not only have a high risk of upper
gastrointestinal haemorrhage, but also usually require anticoagula-
tion therapy to prevent venous thromboembolism. Given these addi-
tive risks, most patients are prescribed gastric protection with a
proton pump inhibitor (PPI). However, PPI exposure is also a risk fac-
tor for AAD / CDI. Literature reports show that patients on PPIs have a
relative risk of 1.69 of contracting CDI compared to patients who are
not taking the medication [12]. The prevalences of AAD and CDI in
PWSCI are reported in the range 14.9 to 30.3% [8,13,14].Diarrhoea can moreover delay rehabilitation, increase the risk of
developing pressure ulcers/delay wound healing and reduce quality
of life (QOL). There is growing interest in probiotics to reduce the risk
of AAD / CDI. An early study identified the use of PPIs and malnutri-
tion or under nutrition risk [8] as possible risk factors for AAD/CDI,
but failed to provide definitive results due to the lack of blinded con-
trol data. We therefore planned a randomized double-blind, placebo-
controlled study to assess the efficacy of the commercially available
probiotic (Lactobacillus casei Shirota: LcS) for the prevention of AAD
and CDI in adults with SCI. The objectives of the study were: (1) to
test the efficacy of daily consumption of a probiotic drink containing
at least 6.5 x 109 live LcS in preventing AAD and CDI in SCI patients,
and (2) to determine whether (malnutrition or) under nutrition risk
and PPI use are a risk factor for AAD/CDI.
2. Methods
2.1. Study design
This study was a prospective, multi-centre, randomized, double-
blind, placebo-controlled study. Patients who had been prescribed
antibiotics were identified and approached for consent. After obtain-
ing written informed consent, study data were collected at the time
of prescribing antibiotics (baseline) and at follow up, set at 7 days
and 30 days after the end of the antibiotic course (Abx+7d, Abx+30d).
The study was conducted within the National Health Service in the
UK. The three centres involved in this study are responsible for about
4550% of all specialist SCI service in the UK.
2.2. Participants
The inclusion criteria were: patients aged  18 years, who had
sustained a SCI, had been admitted to one of the three investigatory
centres, were due to receive antibiotics for an infection, and who
were able to take the study drinks within 48 h of the first dose of anti-
biotic. Patients were excluded from the study for the following rea-
sons: previous recruitment to the study (a patient could not be
recruited more than once) and were excluded if they had antibiotic
use in the 30 days prior to recruitment  although a single dose of
prophylactic antibiotic given 14 to 30 days before recruitment was
permitted. Also, patients with diarrhoea within the seven days prior
to recruitment, with known gastrointestinal disease that could result
in diarrhoea and several other conditions and comorbidities were
also excluded. (Supplement table 1)
Between November 2014 to November 2018, 359 consenting SCI
patients, who were within 48 h of commencing antibiotics, were ran-
domly allocated to receive a fermented milk drink (Yakult: 65 ml)
containing a minimum of 6.5 x 109 colony-forming units (CFU) LcS/
bottle, or placebo daily for the duration of the antibiotic course and
for 7 days thereafter. The study drink was given at the drug round by
nurses. Consumption was monitored on a daily basis by the study
team. Minor non-compliance was defined as: two consecutive days
of not drinking the study intervention; major non-compliance: three
or more consecutive days missed. If participants missed the interven-
tion for more than three days, they were withdrawn from the study.
The participants’ demographics, baseline clinical and nutritional
information were collected. These included age, sex, level of SCI and
completeness of injury using the International Standards for Neuro-
logical Classification of Spinal Cord Injury [15] and cause of SCI. Infor-
mation about nutritional factors, such as weight and height, route of
nutrition, nutrient intake as estimated by food record charts (nil by
mouth, less than half, half, more than half, and all eaten), interrup-
tions and supplementation of nutrition (use of oral nutritional sup-
plements and artificial nutrition support), was collected. Additional
data, which included the use of mechanical ventilation, the history of
intensive care unit stay, the number of medications, the indication,
Fig. 1. Trial Profile. Decision tree for recruitment and randomization.
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were recorded.
The perceived risks of the various antibiotics were used to catego-
rise patients into three groups: “low-risk” antibiotics (metronidazole
and parenteral aminoglycosides), “medium risk” antibiotics (tetracy-
clines, sulphonamides and macrolides) and “high risk” antibiotics
(aminopenicillins, cephalosporins and quinolones) as described in
previous studies [6,8,16] and by the UK National Institute for Health
and Care Excellence [17]. (Supplement table 2)
2.3. Sample size
To estimate the size of the sample, we used data from our previ-
ous study [8], where we found a difference of 17.9% between groups
in the proportion of patients with diarrhoea (56.3% vs 38.4%), which
was used as the target difference for effect size. With alpha=0.05 andpower of 90%, we estimated a sample size of 162 per group (in
G*Power). After accounting for loss to follow-up at 10% (across the
length of the trial), this indicated that 180 participants per trial arm
(resulting in a total sample of 360, with equal allocations to groups)
would be needed.
2.4. Randomization and masking
A random allocation was carried out by the statistical advisor (SPH)
using randomization.com to generate random permutated blocks of
30 for each study site and for previous single dose prophylactic antibi-
otic use (15 to group 1 and 15 to group 2 per block with no stratifica-
tion or minimization), until sample size criteria were met. The
randomization sequence was concealed from the study team. The
study team allocated study drink as per the randomization list and the
team was blinded to patient allocation. Emergency unblinding codes
Fig. 2. Summary of LcS in study outcome measures, including subgroup analysis.
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domization list was forwarded to the product supplier (Yakult Europe
B.V.) by the study data analyst. The product supplier arranged delivery
of product packs to study sites, each with a sticker/code specific for
each participant. The placebo was an acidified milk without LcS with
nutritional values and organoleptic characteristics (appearance, smell,
taste, texture) equivalent to those in the probiotic product. The probi-
otic drink and the placebo were presented in identical packaging to
prevent unblinding by site’s staff. Fig. 1, provides the decision tree of
recruitment and randomization of subjects.
2.5. Primary outcome
The primary outcome was defined as the occurrence of AAD during
and up to 30 days after the antibiotic course finished. The bowel move-
ments were monitored routinely by the nursing staff on the ward using
the Bristol stool scale [18]. Diarrhoea was defined as more than two liq-
uid stools (Bristol stool scale type 5, 6 or 7) in any 24 hour period.
2.6. Secondary outcomes
Whenever diarrhoea was reported, a stool sample was collected
and sent to the hospital laboratory for the detection of C. difficile
toxin. In the present study, CDI was defined by the hospital microbi-
ology laboratory on confirmation of the presence of C. difficile toxin,
but the method of C. difficile toxin detection varied between the labo-
ratories: i.e., screening for glutamate dehydrogenase (GDH) antigen
followed by toxin A and B detection, enzyme immunoassays for C. dif-
ficile toxin A and toxin B, or toxin-producing C. difficile gene detection
by polymerase chain reaction testing, or a combination of these [19].
The study team recorded the occurrence of diarrhoea throughout the
study. The census date was fixed 30 days after the antibiotic course
had finished. The secondary outcomes were (1) the occurrence of CDI
detected by the study site laboratory and (2) to determine if under
nutrition risk and PPI are risk factors for AAD/CDI.2.7. Statistical analysis
The primary statistical analysis was carried out on the basis of
intention-to-treat, with all participants being analyzed according to
their allocated treatment group irrespective of what treatment they
actually received.
Fisher’s exact test and x2 test were used to compare rates of diar-
rhoea, as well as rates of AAD and CDI across categorical variables.
Relative risks with 95% confidence intervals, were used to describe
the treatment effects of LcS.
A series of screening univariate analyses were undertaken. Logis-
tic regressions were used to establish which factors individually
influenced the occurrence of diarrhoea, its duration (and CDI at Abx
+7d and Abx+30d follow up). Linear regression was used for continu-
ous outcome measures for duration of diarrhoea and episodes of diar-
rhoea. Thereafter, statistically significant univariate predictors were
used in, multiple binary logistic regression and multiple regression
analysis to determine statistically significant predictors for AAD, CDI
and other secondary outcomes, after accounting for their relationship
to other pertinent variables. Sub-group analyses were performed
within treatment arms to analyze the following for association with
AAD/CDI occurrence: (i) risk of under nutrition and (ii) use of PPIs. No
allowance for multiplicity was made for the secondary outcomes.
To reduce the bias implicit in utilizing only complete cases, multiple
imputation procedures for the data was used using the SPSS (SPSS ver-
sion 25, Inc, Chicago, IL) multiple imputation function with fully condi-
tional specification (maximum iterations of 500) using a Predictive
Mean Modeling method to produce 10 imputed datasets. The imputa-
tion model included all variables (demographic, clinical and outcomes)
involved in the analyses, with PMM imputed variable limits set for
imputed values to be within the range of available data. Main outcome
variables (i.e. AAD and CDI) were not imputed. These 10 imputed data-
sets were then individually analyzed as normal; thereafter standard
multiple imputation procedures were used to combine themultiple sca-
lar andmultivariate estimates quantities [2021].
Table 1
Baseline characteristics and outcomes summary.
Total number with values (missing,%) LcS group n = 181 Placebo group n = 178
Age
Median (IQ range, range)
351 (8, 2.3%) 53 (28, 1984) 56 (27, 1888)
65 years (%) 50 (27.6%) 48 (27.0%)
Level of SCI 359 (0, 0%)
Level of SCI: Tetraplegia (n,%) 178 (0, 0%) 88 (48.6%) 90 (50.6%)
Level of SCI: Paraplegia (n,%) 181 (0, 0%) 93 (51.4%) 88 (49.4%)
Severity of initial neurological deficit 359 (0, 0%)
AIS15 grade A (n,%) 158 (0, 0%) 85 (47.0%) 73 (41%)
AIS grade B (n,%) 57 (0, 0%) 27 (14.9%) 30 (16.9%)
AIS grade C (n,%) 79 (0, 0%) 40 (22.1%) 39 (21.9%)
AIS grade D (n,%) 65 (0, 0%) 29 (16.0) 36 (20.2%)
Centre 1 255 (0, 0%) 129 (71.3%) 126 (70.8%)
Centre 2 69 (0, 0%) 35 (19.3%) 34 (19.1%)
Centre 3 35 (0, 0%) 17 (9.4%) 18 (10.1%)
Mechanical ventilation (n,%) 359 (0, 0%) 15 (8.3%) 22 (12.4%)
Pressure ulcers (n,%) 359 (0, 0%) 63 (34.8%) 56 (31.5%)
History of previous ITU stay (n,%) 359 (0, 0%) 42 (23.2%) 44 (24.7%)
Number of drugs
Median (IQ range, range)
348 (11, 3.1%) 9 (6, 121) 9 (5, 131)
Proton pump inhibitor (PPI) use (n,%) 348 (11, 3.1%) 68 (37.6%) 64 (36.0%)
Multiple antibiotics (n,%) 359 (0, 0%) 55 (30.4%) 71 (39.9%)
Duration of antibiotics
Median (IQ range, range)
349 (10, 2.8%) 7 (5, 255) 8 (6, 269)
High risk antibiotics (n,%) 359 (0, 0%) 94 (51.9%) 106 (59.6%)
Laxative use (n,%) 348 (11, 3.1%) 154 (85.1%) 150 (84.3%)
At undernutrition risk: SNST 11 (n,%) 350 (9, 2.5%) 64 (35.4%) 59 (33.1%)
Nil by mouth status (n,%) 355 (4, 1.1%) 2 (1.1%) 5 (2.8%)
Use of enteral feeding tube (n.%) 356 (3, 0.8%) 9 (5.0%) 12 (6.7)
At overnutrition risk: BMI>25 kg/m2 (n,%) 343 (16, 4.5%) 78 (43.1%) 81 (45.5%)
Obese: BMI >30 kg/m2 (n,%) 350 (9, 2.5%) 32 (17.7%) 34 (19.1%)
Time to take first study drink after first antibiotic dose 355 (4, 1.1%)
Within 24 h (n,%)  137 (75.7%) 145 (81.5%)
2448 h (n,%)  43 (23.8) 30 (16.9%)
SCI: spinal cord injury; SNST: Spinal Nutrition Screening Tool; BMI: body mass index; ITU: intensive therapy unit.
Data are n (%) unless otherwise stated. AIS= American Spinal Injury Association / International Spinal Cord Society neurological stand scale.15.
Number used to calculate proportions for other characteristics is proportion of patients with available follow up data.
Abx+7d diarrhoea: occurrence of diarrhoea at 7 days after finished antibiotic course, 7 days after they stop intervention (LcS placebo).
Abx+30d diarrhoea: occurrence of diarrhoea at 30 days after finished antibiotic course, 23 days after they stop intervention (LcS/placebo).
Abx+7d CDI: occurrence of C. diff infection at 7 days after finished antibiotic course, 7 days after they stop intervention (LcS/placebo).
Abx+30d CDI: occurrence of C. diff infection at 30 days after finished antibiotic course, 23 days after they stop intervention (LcS/placebo).
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rectly classified cases are reported. For linear regression, adjusted R2
and b coefficients with t-test significance are reported. For all tests, a
p-value of 0.05 or less, or when the 95% CI for OR did not cross 1.0
were considered as statistically significant. Statistical analysis was
performed using the Minitab statistical software (Version 25.0; Mini-
tab, Inc.) and SPSS (Version 19; IBM Corporations).
2.8. Ethical consideration
The present study, conducted according to the guidelines laid
down in the Declaration of Helsinki, received ethical approval from
the National Research Ethics (REC) Committee (reference no. 14/SC/
1101) and approval from the local research and development depart-
ment at each participating site. After the study had been explained
by a research coordinator and all questions had been answered, each
participant signed an informed consent form prior to trial initiation.
The original study protocol was registered at ISRCTN
(IRCTN13119162). The study steering group was set up in July 2014
and the study commenced its recruitment in November 2014.
Changes were recommended to the original, approved protocol to
improve recruitment specifically in relation to the inclusion and
exclusion criteria of patients’ enrolment. The new version of the pro-
tocol was developed in accordance with the consolidated standards
of reporting trials 2010 guideline and subsequently approved by the
sponsor and funder and the REC. [Supplementary File 1]
A register was kept of all patients who withdrew from the study. The
reason for consent withdrawal was documented, if provided by theparticipants, along with the following core patient characteristics: age,
gender and level and severity of SCI. Tomonitor the progress and conduct
of the study, all investigators attendedmeetings before the study andmet
for communal bi-annual updates and end of studymeeting in Jan 2019.
The study was additionally monitored by an external Clinical
Research Associate (PHARMExcel) according to applicable provisions
of the sponsor’s subcontractors monitoring procedures, in confor-
mance with ICH-GCP FDA guidelines, ISO 14,155 and UK-specific
laws/regulations.
2.9. Definition of under nutrition risk
Participants were considered at risk of under nutrition on the
basis of the Spinal Nutrition Screening Tool (SNST) [22]. The SNST
assesses eight criteria, of which the majority are recognized as pre-
dictors or symptoms of under nutrition: history of recent weight
loss; body mass index; level of SCI; presence of co-morbidity; skin
condition; appetite; ability to eat. Each step of screening has a score
of up to 5 and the total score reflects the participant’s degree of risk.
A score of 010 suggests a low risk, 1115 a moderate risk and >15
suggests a high risk of under nutrition. Participants who had a SNST
score 10 were considered at low risk, and all those with a SNST
score  11 were considered at increased risk.
3. Role of funding source
This study was funded by Yakult Honsha Co. Ltd. The funder did
not have any role in the design of the study, the collection, analysis,
Table 2
Summary of severe adverse events.
Total number with values (missing,%) LcS group n = 181 Placebo group n = 178
Severe Adverse Events (%) 359 (0, 0%) 2.2% (4) 3.4% (6)
Unexpected SAE 4 6
Nature of SAE
Transfer to other hospital (cardiology) 1
High dependency unit admission 3
Intensive Care Unit admission 2
Death 2 2
6 S. Wong et al. / EClinicalMedicine 40 (2021) 101098or interpretation of the data, the writing of this manuscript, or the
decision to submit this manuscript for publication. Dr Samford Wong
as chief investigator and corresponding author had full access to the
final dataset and made final decision to submit for publication.4. Results
Over the 72 months of the study period, 459 patients were
approached by the study team; 48 (10.5%) patients refused to partici-
pate in the study, 44 (9.6%) potentially eligible patients were missed
because of the tight recruitment timeframe, and eight (1.7%) were
excluded as insufficient study drinks were available at the time. Of
the 359 patients who met the inclusion criteria and agreed to partici-
pate in the study, 41 (11.4%) participants withdrew during the study.
The participant flow is summarized in Fig. 1.
The baseline characteristics of the 359 patients (median age: 55, IQ
range: 27; 26.7% female; 85.6% Caucasian; 49.6% tetraplegia; 44% com-
plete SCI), and the outcomes summary are summarized in Table 2. SCI
was traumatic in origin (n = 246, 68.9%) and non-traumatic in 111 case
(31.1%). The median onset of SCI was 157 days (IQ range: 2661 days).
The prevalence of risk for under nutrition was 35.1% (n = 123) at
the time of recruitment and 63 (17.7%) were malnourished on dieti-
tian assessment. We compared participants’ nutrient intake in a small
group of selected patients using the food record chart. No difference
was observed between the LcS (n = 6) and placebo (n = 6) groups
with regards to the estimated daily intake of energy, protein and die-
tary fibre. 132 (37.9%) of 348 participants were prescribed PPI
(Table 1).
Most participants (64.9%) received one antibiotic as their entry
criterion to the study, but 23.4% received two, 7.5% received three
and 4.2% received four or more antibiotics. A total of 25 different anti-
biotics were recorded in the present study: the oral route was used in
46.6% and the intravenous route was used in 53.4% of participants.
The median length of antibiotic course was 8 days (IQ range: 5;
Range: 2 to 69 days); no statistically significant differences with
regard to nature or duration of antibiotic intake were observed
between the LcS and the placebo groups. The indications for antibi-
otic treatment, in descending order, were as follows: urinary tract
infections (n = 176, 46.1%), respiratory tract infections (n = 49, 12.8%),
post-operative infections (n = 42, 11.0%), sepsis (n = 34, 8.9%), pres-
sure ulcers (n = 25, 6.5%), wound infections (n = 19, 5.0%), cellulitis
(n = 8, 2.1%), abscess (n = 4, 1.0%), toe/finger infection (n = 4, 1.0%),
osteomyelitis (n = 3, 0.8%), tooth infections (n = 3, 0.8%) and others
(n = 15, 3.9%). The number of participants on high-risk antibiotics
were closely comparable between the LcS and placebo groups (51.9%
in LcS group and 59.6% in placebo group).
At baseline, the LcS and placebo groups were similar with respect
to demographic and clinical characteristics, which included: age,
onset of SCI, those with tetraplegia and those with complete SCI, the
percentage who were on mechanical ventilation, the percentage with
pressure ulcers, the percentage with previous history of Intensive
Therapy Unit (ITU) stay; laxative use; PPI use, body mass index (BMI),
percentage of nil-by-mouth status and use of enteral feeding tubes
(Table 1).Ten (2.8%) severe adverse events were reported in this study. They
were not apparently related to the use of investigational product and
occurred almost equally in the two groups (LcS: n = 4, 2.2% v Placebo:
n = 6, 3.4%). (Table 2)
5. Primary outcome
5.1. Antibiotic associated Diarrhoea
The primary analysis was intention to treat and included all
patients with available end-point data. The overall prevalence of AAD
was 32.1% at 7 days, and 43.6% at 30 days follow up. There was no sta-
tistically significant difference between the LcS and placebo groups
for the prevalence of AAD at 30 day follow up (45% v 42.1%, RR:
1.071, 95%CI: 0.8 to 1.4, p = 0.639). (Table 3)
6. Secondary outcomes and predetermined subgroup analysis
There was no statistically significant difference between the LcS
and placebo groups for the prevalence of AAD at 7 days follow up
(32.5% v 31.6%, RR: 1.03, 95% CI: 0.751.42, p = 0.858) and duration
of AAD (median: days, 5 v 6, p = 0.597) or the number of episodes of
AAD (median, 0 v 0, p = 0.527). (Table 3)
6.1. Patients on proton pump inhibitors
There was no statistically significant difference between patients
on PPI and those who were not, in the prevalence of AAD at Abx+7d
(35.7% v 28.6%, x2: 0.823, p = 0.36) and AAD at Abx+30d (52.2% v
35.5%, x2: 3.264, p = 0.07). However, in the group of patients who
were on regular PPI, LcS use was associated with a lower risk of AAD
at 7 (19% v 35.7%, RR: 0.53, 95% CI: 0.290.99, p = 0.040) and 30 days
follow up (28% v 52.2%, RR: 0.54, 95% CI: 0.320.91, p = 0.015) when
compared with placebo (Fig. 2 and supplement table 3.1). No differ-
ence was observed between LcS and placebo in the incidence of AAD
in those patients who did not take PPIs. (Supplement table 3.2)
6.2. Malnutrition risk
Overall, participants at malnutrition risk were found to have a sig-
nificantly higher prevalence of AAD at 7 (43.6% v 24.7%, RR: 1.76, 95%
CI: 1.282.44, p = 0.001) and at 30 days follow up (60.4% v 35.7%, RR:
1.69, 95% CI: 1.302.2, p < 0.001) Participants who were allocated to
LcS or placebo and at risk of malnutrition were found to have a statis-
tically significantly increased prevalence of AAD at Abx+7d and at
Abx+30d (Supplement table 3.3 and 3.4)
7. Other secondary outcomes
7.1. Clostridioides Difficile infection
Overall, 15 samples were positive for C. difficile toxin at 7 day fol-
low up. The incidence of CDI was 5.5%. There was no statistically sig-
nificant difference between the LcS and placebo groups at 7 (4.2% v
Table 3
Abx+7d diarrhoea: occurrence of diarrhoea at 7 days after finished antibiotic course, 7 days after they stop intervention (LcS placebo) Abx+30d diarrhoea: occurrence of
diarrhoea at 30 days after finished antibiotic course, 23 days after they stop intervention (LcS/placebo). Abx+7d CDI: occurrence of C. diff infection at 7 days after finished
antibiotic course, 7 days after they stop intervention (LcS/placebo).
Outcome measures Total number with values
(missing/359, %)
LcS group Placebo group Absolute Risk (95% CI) Relative Risk (95% CI) p
Primary outcome
AAD – Abx+30d (n, %) 257 (102, 28.4%) 45% (59 / 131) 42.1% (53 /126) -0.03 (-0.149 to 0.090) 1.071 (0.810 to 1.415) 0.639
Secondary outcomes
AAD – Abx+7d (n, %) 315 (44, 12.3%) 32.5% (53 /163) 31.6% (48 /152) -0.009 (-0.111 to 0.093) 1.03 (0.746 to 1.421) 0.858
CDI – Abx+7d (n, %) 275 (84, 23.4%) 7.1% (10 /141) 3.7% (5 /134) -0.034 (-0.092 to 0.023) 1.901 (0.667 to 5.416) 0.22









MannWhitney U z p
Duration of diarrhoea (days) 258 (101,28.1%) 5 (0, 0-23) 6 (0, 0-31) 8071.5 -0.528 0.597
Episode of diarrhoea 334 (25, 7.0%) 0 (0; 0-7) 0 (0, 0-7) 13420.5 -0.632 0.527
S. Wong et al. / EClinicalMedicine 40 (2021) 101098 72.2%, p = 0.362) and at 30 days follow up (1.8% v 1.9%, p = 0.963)
(Table 3)
Risk factors for antibiotic associated diarrhoea / Clostridioides diffi-
cile infection
The multivariate logistic/regression analysis revealed independent
risk factors for AAD at Abx+7d: age older than 65 years, use of high-risk
antibiotics, study site and number of drugs. The risk factors for AAD at
Abx+30d were mechanical ventilation, study site and number of laxa-
tives. The risk factors for frequent diarrhoea were age 65 or above, study
site, being GDH positive and number of drugs. The risk factors for
increased duration of diarrhoea were being nil by mouth, malnutrition
as assessed by dietitian, number of drugs and study site. The risk factors
for CDI at Abx+7d were being GDH positive and having a history of
weight loss, whereas those for CDI at Abx+30d were being GDH positive
and having a long duration of antibiotic treatment. Supplement Table 4
provides a summary of the univariate and multivariate results.
8. Discussion
This is the first randomised placebo-controlled trial with an ade-
quate sample size in a group of patients with SCI, which has evalu-
ated the efficacy of LcS for the prevention of AAD and CDI. Although
this specific probiotic drink could not prevent AAD in all SCI patients,
finding suggests that taking LcS is associated with a lower risk of AAD
in people with SCI who are on regular PPI therapy.
The present study’s conclusion is different from our earlier open-
labelled study [8]. The discrepancy in the overall effect may result from
the smaller size of the earlier underpowered study (158 vs 359 patients)
or from differences in the study design. The present study defined AAD
as 2 liquid stools (Bristol Stool Scale type 5, 6 or 7) for a 24-hour
period, whereas the previous trial required3 days [8]. This altered def-
inition may have led to a failure in distinction between clinically rele-
vant AAD and loose stool due to neurogenic bowel as a result of SCI.
Indeed, the definition of AAD varies widely between published studies.
For example, Rajkumar et al. [6] defined diarrhoea as 2 loose stools,
Bristol 6 or 7 a day for 3 days, whereas Allen et al. [7] and Helps et al.
[9] defined diarrhoea from 3 loose stools, Bristol 5, 6 or 7 in a single
24-hour period. The definition for CDI also varies. Using more standar-
dised definitions of study outcomes in AAD/CDI is now improving the
quality of and aiding interpretation of newer research studies, especially
important for systematic reviews andmeta-analyses.
`The inclusion of patients treated in different SCI centres could be
considered a strength, but can also be regarded as a weakness. Infec-
tion control policies, AAD/CDI definition and antibiotic management
were different in the participating SCI centres, thus the influence of
these factors on the study results could not be excluded.
The present study suggests malnutrition risk could increase the
incidence of AAD in 30 days follow up (60.4% v 37.5%, p< 0.01). Theseresults are in agreement with results of a similar published study [8].
Previous research has suggested that consumption of oral nutritional
supplements in patients with known malnutrition risk could improve
clinical outcomes [23]. Clinicians, therefore should be aware of the
need to identify and treat malnutrition which will prevent malnutri-
tion related complications [2425].
The present study’s incidence of AAD (32.1%) is similar to some
previous studies in patients with SCI (14.936%) [6,7,8] and seems
higher than studies conducted in general populations (10.8  17.9%)
[6,7]. This may be attributed to a longer follow-up period (30 days)
than in many of the other published trials (often only 714 days) [6];
diarrhoea may occur up to 2 months after discontinuing antibiotic
treatment [26].
Current evidence remains unclear in whether probiotics could
reduce the incidence of AAD/CDI in general hospitalised populations
[5,6,7]. The complexity of probiotic use is not just strain-, product-,
dose- and disease specific, but also includes defining when the probi-
otic should be administered and the duration of its use; all need to be
considered. The present study dose of a minimum of 6.5 x 109 CFU
LcS was selected based on the previous trial’s data [8]. LcS is well tol-
erated in clinical settings and has been used in a broad range of
patients [27,28]. However, dose and type of probiotic vary between
published studies. For example, Allen et al. [7] used a mixed strains
probiotic (L. acidophilus CUL60, CUL21, B. bifidum CUL20, B. lactis
CUL34 in 6 x 109 CFU /day), Helps et al. [9] used a single strain probi-
otic (LcS in 13 x 109 CFU /day), and Rajkumar et al. [6] used mixed
strains (L. casei immunitas DN-114,001 in 10 x 109 CFU /day) as did
Selinger et al [10] (VSL#3 in 900 x 109 CFU /day).
The compliance with LcS therapy in the present study was good
(92.4%), with no known severe adverse events directly related to LcS.
It is possible that a higher dose might have yielded a greater benefit.
However, the effect of increasing dosage of probiotics should be mon-
itored carefully as unexpected adverse events may also occur.
Another important criterion for any probiotic is that the strains
used survive the passage through the stomach and arrive in a viable
state in the small intestine and colon. LcS has been shown to survive
and be well tolerated in the upper gastrointestinal tract and reach
the large intestine in a viable state [2930].
The present study does not provide support for a general use of
LcS to prevent AAD in SCI patients but suggests that LcS may help to
prevent AAD in SCI patients taking PPI regularly. Confirmatory stud-
ies are now needed to allow translation of this apparent therapeutic
success into improved clinical outcomes. Further research should
define the most appropriate target populations. Study designs using
standardized definitions of AAD and CDI will help to evaluate the
effect of probiotics in preventing AAD/CDI as well as in providing
more homogeneous evidence for future systematic review and meta-
analysis.
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